Dr. David M. Routman, M.D.
Claim this profileMayo Clinic in Rochester
Studies Skin Cancer
Studies Oropharynx Cancer
2 reported clinical trials
3 drugs studied
Area of expertise
1Skin Cancer
HPV positive
Stage III
p16 positive
2Oropharynx Cancer
HPV positive
Stage III
p16 positive
Affiliated Hospitals
Clinical Trials David M. Routman, M.D. is currently running
Biomarker-Guided Therapy
for Oropharyngeal Cancer
This phase II trial examines the use of blood-based biomarkers is to help inform decision making for treatment and radiation therapy for patients with human papillomavirus (HPV) positive oropharyngeal squamous cell cancers. The standard treatments for head and neck cancers are radiation therapy with chemotherapy or surgery potentially followed by radiation therapy with or without chemotherapy. Radiation therapy uses high energy rays to kill tumor cells and shrink tumors. Giving chemotherapy along with radiation may kill more tumor cells. However, the cancer can recur or can spread to other parts of the body and all treatments can be associated with side effects. The purpose of this study is to evaluate a blood-based biomarker, using the NavDx testing device, for head and neck cancers in order to see if it can help improve selection of the intensity of treatment in order to best balance the side effects of treatment with the goal of decreasing cancer recurrence. This test could aid in early detection of recurrence and salvage therapy.
Recruiting1 award Phase 2
PDS0101 Vaccine + Pembrolizumab
for Oropharyngeal Cancer
This phase I/II trial studies how well PDS0101 alone or in combination with pembrolizumab works to shrink tumor in patients with human papillomavirus-associated oropharynx cancer that has spread to nearby tissue or lymph nodes (locally advanced). PDS0101 is a vaccine made from specific peptides that may help the body build an effective immune response to kill tumor cells. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving PDS0101 with or without pembrolizumab may kill more tumor cells in patients with locally advanced human papillomavirus-associated oropharynx cancer before surgery so that it may make the tumor smaller and may reduce the amount of normal tissue that needs to be removed.
Recruiting2 awards Phase 1 & 2
More about David M. Routman, M.D.
Clinical Trial Related2 years of experience running clinical trials · Led 2 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments David M. Routman, M.D. has experience with
- Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101
- Pembrolizumab
- Blood-Based Biomarkers
Breakdown of trials David M. Routman, M.D. has run
Skin Cancer
Oropharynx Cancer
Oropharyngeal Cancer
Oropharyngeal Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does David M. Routman, M.D. specialize in?
David M. Routman, M.D. focuses on Skin Cancer and Oropharynx Cancer. In particular, much of their work with Skin Cancer has involved HPV positive patients, or patients who are Stage III.
Is David M. Routman, M.D. currently recruiting for clinical trials?
Yes, David M. Routman, M.D. is currently recruiting for 2 clinical trials in Rochester Minnesota. If you're interested in participating, you should apply.
Are there any treatments that David M. Routman, M.D. has studied deeply?
Yes, David M. Routman, M.D. has studied treatments such as Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101, Pembrolizumab, Blood-Based Biomarkers.
What is the best way to schedule an appointment with David M. Routman, M.D.?
Apply for one of the trials that David M. Routman, M.D. is conducting.
What is the office address of David M. Routman, M.D.?
The office of David M. Routman, M.D. is located at: Mayo Clinic in Rochester, Rochester, Minnesota 55905 United States. This is the address for their practice at the Mayo Clinic in Rochester.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.